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At a global level, cardiovascular diseases (CVDs) are the 
leading cause of mortality, claiming almost 18 million lives 
annually. Throughout the last decade, this CVD burden is 
still increasing both in terms of deaths and disability-adjusted 
life years. Age-standardized death and DALY rates however 
are decreasing, which points to the fact that population ageing 
plays an important role in the evolution of the CVD rates and 
will continue to do so in the future (1,2). 
In terms of costs, CVD represent between 7.6% and 
21.0% of national health expenditures, mainly due to 
ischemic heart disease and stroke. The largest share of 
expenditure (half or more) goes to hospital inpatient care, 
followed by spending on pharmacological treatment (3-7). 
Most existing CVD cost studies consider the costs of care 
after a specific cardiovascular event, pointing out the need for 
public health programs or interventions to reduce this burden 
(3,6). In order to allocate resources to public health programs, 
more should be known about the cost of those programs.
Recently, Shaw et al. published an article on the 
10-year cost of CVD in an American cohort within the 
Multi-Ethnic Study of Atherosclerosis (MESA), a cohort 
of asymptomatic and apparently healthy individuals (45 to 
84 years of age) (8).
The reported increase of cardiovascular risk factors 
among these asymptomatic individuals, i.e., diabetes 
prevalence increased from 10.0% to 19.3%, hypertension 
from 44.9% to 57%, dyslipidaemia from 37.3% to 52.8%, 
means a higher need for—and use of—health care services 
in the cohort. Only 30% of individuals did not have an 
echocardiogram, exercise test or invasive angiography (8).
The 10-year (cumulative) health care cost was reported 
at just above $23,000 per patient; 78% of which was caused 
by CVD drugs, and even higher shares for individuals with 
diabetes (87%) and dyslipidaemia (90%) (8). This pattern 
differs from other CVD cost-of-illness studies which 
indicate a higher share of costs towards inpatient care. 
This is probably because cost-of-illness studies are focused 
in patients having experienced a CVD, while Shaw et al. 
focused on a cohort before any CVD event occurred.
Shaw et al. note the large impact on costs of risk profile 
on the one hand, and of the socio-economic factors on 
the other hand (8). Costs increased significantly with a 
higher Framingham risk score, coronary artery calcium 
score or elevated C-reactive protein: cumulative costs 
in low and high-risk profiles are associated with a mean 
cost of respectively $8,000 and $36,000, up to a 15-fold 
cost increase between those risk profiles. Low-risk status 
persons accounted for 5.2% of total costs; while high-risk 
status persons were responsible for 48% of costs. Other 
studies have already pointed out this cost increase related to 
risk factors. For example, Goetzel et al. indicated that the 
combined contribution of risk factors for heart disease and 
stroke among US employees predicted cost increases by 
214% and 62%, respectively (9).
This prevalence of combined risk factors is on the rise 
and increases the probability of multi-morbidity, which in 
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turn elevates costs. In 2013–2014, the US prevalence rate 
was 59.6% with over one fifth (22.7%) of individuals having 
4 or more morbidities (10). Aside from risk profile, social 
determinants such as insurance, education and age strongly 
impact not just health outcomes, but costs as well (8).
The range of determinants affecting CVD-related costs 
indicates the need for CVD-focused policies but also for 
preventive policies or programs. 
Shaw et al. encouraged public health strategies such 
as early screening and targeted preventive programs 
in order to address this set of issues (8). In fact, cost-
effectiveness of CVD screening policies in high risk 
groups is an increasingly important research trend because 
of its potential for health gains. While tools such as the 
Framingham Risk Score (FRS) can play an important 
role in the detection of different risks individuals, leading 
towards different clinical approaches such as different 
screening intervals (11), other screening approaches like 
non-laboratory single screening or multistage might be 
more cost-effective (12). 
Preventive programs targeted at high-risk groups 
can take many forms; interventions in the context of the 
broader population or within smaller communities can be 
effective in addressing multiple lifestyle-related risk factors. 
Successful examples such as the Västerbotten Intervention 
Programme can serve as a reference (13).
Including the full range of cost elements (i.e., including 
productivity losses due to morbidity and mortality, informal 
care, early retirement costs etc.) may strongly influence cost 
effectiveness studies on CVD prevention policies and, thus, 
studies addressing the different patterns of CVD prevention 
costs are important.
Finally, while there is already some literature and an 
increasing focus on performing economic evaluations of 
CVD prevention programs (14-16), there is still a high 
potential for investment in this field of research, mainly in 
primary prevention. Additionally, the standardization of 
methods in order to compare and apply different programs 
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